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Recombinant adeno-associated virus (AAV) vectors are 
one of the most widely used gene transfer systems in 
research and clinical trials. AAV can transduce a wide range 
of biological tissues, however to date, there has been no 
investigation on targeted AAV transduction of the enteric 
nervous system (ENS). Here, we examined the efficiency, 
tropism, spread, and immunogenicity of AAV transduc-
tion in the ENS. Rats received direct injections of various 
AAV serotypes expressing green fluorescent protein (GFP) 
into the descending colon. AAV serotypes tested included; 
AAV 1, 2, 5, 6, 8, or 9 and the AAV2 and AAV8 capsid 
mutants, AAV2-Y444F, AAV2-tripleY-F, AAV2-tripleY-F+T-V, 
AAV8-Y733F, and AAV8-doubeY-F+T-V.  Transduction, as 
determined by GFP-positive cells, occurred in neurons 
and enteric glia within the myenteric and submucosal 
plexuses of the ENS. AAV6 and AAV9 showed the highest 
levels of transduction within the ENS. Transduction effi-
ciency scaled with titer and time, was translated to the 
murine ENS, and produced no vector-related immune 
response. A single injection of AAV into the colon covered 
an area of ~47 mm2. AAV9 primarily transduced neurons, 
while AAV6 transduced enteric glia and neurons. This is 
the first report on targeted AAV transduction of neurons 
and glia in the ENS.
Received 27 June 2014; accepted 30 December 2014; advance online  
publication 3 February 2015. doi:10.1038/mt.2015.7
INTRODUCTION
Recombinant adeno-associated virus (AAV) is one of the most 
widely used gene therapy systems in research and clinical trials.1–3 
AAV is favored over other viral vectors due to its lack of pathogen-
icity and the ability to establish expression within both dividing 
and mature nondividing cells of multiple lineages. Further, AAV 
vectors can achieve high levels of transduction within weeks that 
are maintained over the lifetime of an organism.2,4 AAV vectors 
can efficiently transduce many different biological tissues includ-
ing; muscle, liver, brain, lung, and retina (reviewed in ref. 4). 
Although there have been reports that AAV can transduce cells 
of the gut following systemic or peroral delivery,5–7 to date, there 
has been no focused investigation on the ability of AAV to directly 
transduce cells of the enteric nervous system (ENS) following tar-
geted injections.
The ENS is a division of the autonomic nervous system. The 
ENS coordinates control of enterocyte secretion, nutrient and 
fluid absorption, blood flow, and motor function in the gastroin-
testinal (GI) system. The ENS consists of an estimated 100 million 
neurons, which are embedded in the gut wall, spanning from the 
esophagus to the anus. These neurons are organized into ganglia 
located in either the myenteric plexus (MP) or submucosal plexus 
(SMP). The myenteric plexus is located between the circular and 
longitudinal muscle, while the submucosal plexus is located just 
below the mucosa in the lumen of the gut. Although the ENS is 
connected to the CNS, the ENS is composed of integrative neuro-
nal circuits, which can control most gut functions independent of 
CNS connections.8
Abnormalities of the ENS cause disruptions in GI function 
that manifest in functional disorders such as gastroparesis, irri-
table bowel syndrome, Allgrove syndrome, hypertrophic pyloric 
stenosis, Hirschprung disease, or intestinal neuronal dysplasia. 
Many of these disorders are not life threatening but they do cause 
extreme patient discomfort and reduced quality of life.9 However, 
in some instances, the etiological root of a disease may begin in 
the ENS and spread to other areas of the body. For example, GI 
dysfunction shows a high degree of comorbidity with Parkinson’s 
disease (PD), and the hypothesis that PD pathology originates in 
the gut has gained support.10–13 As such, the ENS has garnered 
increased attention in the study of neurodegenerative disease.
Currently, available model systems for studying disease and 
dysfunction of the ENS are lacking and rely heavily on the use of 
psychological stress, toxicants, or transgenic animals.14 However, 
due to the inherent shortcomings of these model systems (e.g., the 
presence of off target effects due to systemically delivered agents 
or developmental compensations associated with germline muta-
tions),15–17 a more elegant and effective way to study ENS func-
tion or dysfunction is needed. Accordingly, the ability of AAV to 
transduce cells of adult animals offers a large advantage over other 
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transgenic animal models. Furthermore, targeted use of AAV 
allows for both spatial and temporal control of genetic overexpres-
sion or knockdown, which could be used to model and potentially 
treat ENS dysfunction in discrete areas, or even phenotypically 
distinct cell types, of the GI system.
Although AAV vectors hold great potential for studying both 
the function and dysfunction of the ENS, to date little is known 
about the transduction profile of AAV in the ENS. The purpose 
of the current study was to examine the ability of various AAV 
serotypes to infect cells of the ENS. Adult rats received direct 
injections of AAV expressing green fluorescent protein (GFP) into 
the wall of the descending colon. We compared the transduction 
efficiencies of wild-type (WT) AAV serotypes 1, 2, 5, 6, 8, or 9 as 
well as several capsid mutants based on AAV2 and AAV8 vectors, 
which have exhibited increased transduction in other organs.18–22 
The time- and titer-dependent efficiency, tropism, and spread of 
AAV transduction as well as any inflammatory response were 
evaluated within the MP and SMP. Finally, we investigated the 
ability to translate the current technique to other areas of the GI 
tract and other species.
RESULTS
Transduction efficiency of AAV in the ENS
In order to determine the transduction efficiency of various 
serotypes of AAV in the ENS, adult rats received direct injec-
tions of AAV expressing GFP under the control of the hybrid 
chicken β-actin/cytomegalovirus promoter into the wall of the 
descending colon. One month following injection, GFP-positive 
cells were quantified and used as an index of transduction effi-
ciency. All unmodified WT serotypes tested exhibited some 
expression within the ENS; however, there was differential trans-
duction efficiency between serotypes. Within the MP, AAV1 
(2.8 ± 1.6 cells/mm2; Figure 1a,c) and AAV2 (3.3 ± 1.4 cells/
mm2; Figure 1a,d) showed low levels of expression. In contrast, 
AAV6 (16.4 ± 3.6 cells/mm2; Figure 1a,f) and AAV9 (15.7 ± 2.5 
cells/mm2; Figure 1a,h) showed the highest levels of expression 
Figure 1  Transduction efficiency of recombinant adeno-associated virus (AAV) in the myenteric plexus (MP) of the enteric nervous system: 
a comparison across serotypes 1, 2, 5, 6, 8, and 9. Adult male rats received direct injections of AAV (6 × 5 µl injections at 1.3 × 1012 vg/ml) into the 
wall of the descending colon and were sacrificed one month later, at which time the MP was dissected and native fluorescence was viewed under a 
fluorescent microscope. (a) Transduction efficiency of AAV1, 2, 5, 6, 8, and 9, was measured by the quantification of green fluorescent protein (GFP) 
expressing cells in the MP. Columns represent mean number of GFP-positive cells, expressed as cells/mm2, + 1 SEM (n = 4–6/group). AAV6 and 9 
exhibited significantly greater numbers of GFP positive cells than AAV1 and AAV2. (b) The percent of HUc-positive cells transduced for each respec-
tive serotype. Table represents percent of HUc cells colocalized with GFP ± SEM (n = 4–6/group). (c–h) Shows representative images of GFP-positive 
cells in the MP following transduction by AAV1, 2, 5, 8, and 9. Scale bar in (h) represents 100 µm and applies to panels (c–g). * Indicates significantly 
different than AAV1 and AAV2 (P < 0.05).
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and exhibited significantly more GFP-positive cells than AAV1 
and AAV2. AAV5 (10.1 ± 0.7 cells/mm2; Figure 1a,e) and AAV8 
(5.6 ± 1.4 cells/mm2; Figure 1a,g) showed moderate expression, 
however there were no significant changes in GFP cell number 
associated with these groups. In addition to quantifying the num-
ber of GFP-positive cells/mm2, the percent of HUc (a pan neu-
ronal marker) positive cells transduced within the injected area 
were also quantified. The serotype dependent changes in the per-
cent of HUc-positive cells transduced in the MP roughly mirrored 
changes in GFP-positive cells/mm2, with AAV1 (2.7 ± 1.4%) and 
AAV2 (3.6 ± 1.4%) transducing a low percent of neurons within 
the MP (Figure 1b). AAV6 (32.5 ± 7.3%) and AAV9 (31 ± 13.3%) 
transduced a significantly higher percent of HUc positive neu-
rons in the MP than AAV1 and AAV2 (Figure 1b). Finally, AAV5 
(19.2 ± 2.6%) and AAV8 (12.8 ± 0.2%) transduced an intermedi-
ated proportion of neurons in the MP, and showed no significant 
differences from other serotypes examined.
A similar pattern of transduction was observed within the 
SMP, and there were no differences in the transduction effi-
ciency between the MP and SMP. AAV1 (3.9 ± 1.2 cells/mm2; 
Figure  2a,c) and AAV2 (2.8 ± 1.1 cells/mm2; Figure 2a,d) dis-
played low levels of transduction with sparse GFP-positive 
cells throughout the SMP. Again, AAV6 (14.7 ± 4.6 cells/mm2; 
Figure  2a,f) and AAV9 (11.9 ± 1.7 cells/mm2; Figure 2a,h) 
showed the highest level of transduction and had significantly 
greater numbers of GFP-positive cells than AAV1 and AAV2. 
Within the SMP, AAV5 (9.1 ± 2.2 cells/mm2; Figure 2a,e) and 
AAV8 (5 ± 1.8 cells/mm2; Figure 2a,g) displayed moderate levels 
of expression similar to that observed in the MP. Within the SMP, 
the changes observed between serotypes in the number of GFP-
positive cells/mm2 were similar to the percent of neurons trans-
duced. AAV6 (36.4 ± 15.2%) and AAV9 (32.8 ± 10.1) transduced 
significantly more HUc-positive cells than AAV1 (7.9 ± 2.9%) and 
AAV2 (2.7 ± 2.7%; Figure 2b). AAV5 (21.8 ± 5.2%) and AAV8 
Figure 2 Transduction efficiency of recombinant adeno-associated virus (AAV) in the submucosal plexus (SMP) of the enteric nervous system: 
a comparison across serotypes 1, 2, 5, 6, 8, and 9. Adult male rats received direct injections of AAV (6 × 5 µl injections at 1.3 × 1012 vg/ml) into the 
wall of the descending colon and were sacrificed one month later, at which time the SMP was dissected and viewed under a fluorescent microscope. 
(a) Transduction efficiency of AAV1, 2, 5, 6, 8, and 9 was measured by the quantification of green fluorescent protein (GFP) expressing cells in the 
SMP. Columns represent mean number of GFP-positive cells, expressed as cells/mm2, + 1 SEM (n = 4–6/group). AAV6 and 9 exhibited significantly 
greater numbers of GFP-positive cells than AAV1 and AAV2. (b) The percent of HUc-positive cells transduced for each respective serotype. Table rep-
resents the percent of HUc cells colocalized with GFP ± SEM (n = 4–6/group). (c–h) Representative images of GFP-positive cells in the SMP following 
transduction by AAV1, 2, 5, 8, and 9. Scale bar in (h) represents 100 µm and applies to panels (c–g). * Indicates significantly different than AAV1 
and AAV2 (P < 0.05).
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(15.7 ± 6.53) transduced an intermediate percent of neurons com-
pared to the other serotypes (Figure 2b).
We next compared the transduction of unmodified AAV 
serotypes to that of several AAV2- and AAV8-based capsid 
mutants. These capsid mutants showed no significant changes 
in the number of GFP-positive cells/mm2 or the percent of neu-
rons transduced in either the MP or the SMP, compared to their 
parent serotypes. AAV2-Y444F transduced 2.5 ± 2.5 cells/mm2 in 
the MP (Supplementary Figure S1a,d) and 5.7 ± 2.1 cells/mm2 
in the SMP (Supplementary Figure S1g,j) corresponding to 
6.5 ± 6.5% of HUc cells in the MP (Supplementary Figure S1b) 
and 21.2 ± 6.7% of HUc-positive cells and SMP (Supplementary 
Figure S1h). AAV2-tripleY-F transduced 3.9 ± 1.4 cells/mm2 
in the MP (Supplementary Figure S1a,e) and 1.6 ± 0.6 cells/
mm2 in the SMP (Supplementary Figure S1g,k) corresponding 
to 5.8 ± 2.9% and 6.4 ± 2% of HUc-positive cells transduced in 
the MP and SMP, respectively (Supplementary Figure S1b,h). 
AAV2-tripleY-F+T-V transduced 8 ± 1.5 cells/mm2 in the MP 
Figure 3 Neuronal tropism of recombinant adeno-associated virus (AAV) transduction in the myenteric plexus (MP): serotypes 1, 2, 5, 6, 8, 
and 9. Adult male rats received direct injections of AAV (6 × 5 µl injections at 1.3 × 1012 vg/ml) into the wall of the descending colon and were sacri-
ficed one month later, at which time the MP was dissected. MP tissue was stained for the neuronal marker HUc (red) and the enteric glia marker, glial 
fibrillary acidic protein (GFAP; blue). Following the MP was viewed under a fluorescent microscope and the transduction of neurons in the MP was 
determined by examining the colocalization of green fluorescent protein (GFP; green) expression in HUc-positive cells (colocalization appears yellow). 
Neuronal transduction was observed for all serotypes examined. Representative images of neuronal transduction are shown for AAV1 (a–d), AAV2 
(e–h), AAV5 (i–l), AAV6 (m–p), AAV8 (q–t), and AAV9 (u–x). Scale bar in (x) represents 100 µm and applies to panels (a–w).
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(Supplementary Figure S1a,f) and 3 ± 0.8 cells/mm2 in the SMP 
(Supplementary Figure S1g,l), corresponding to 13.6 ± 2.8% and 
15.5 ± 8.8% HUc-positive cells transduced in the MP and SMP, 
respectively (Supplemnetary Figure S1b,h).
The AAV8 capsid mutant vectors tested, AAV8-Y733F 
(Supplementary Figure S2a–d,f,i) and AAV8-doubleY-F+T-V 
(Supplementary Figure S2a–d,g,j), did not show any significant 
increases in transduction over WT AAV8 vector in either the 
MP (5 ± 2.9 cells/mm2 and 20.7 ± 6.1% of HUc cells for AAV8-
Y733F; 12.9 ± 7.3 cells/mm2 and 25.2 ± 15.3% of HUc cells for 
AAV8-doubleY-F+T-V) or SMP (4.2 ± 1 cells/mm2 and 8.2 ± 1.6% 
of HUc cells for AAV8-Y733F; 14 ± 3.9 cells/mm2 and 26.9 ± 9.7% 
of HUc cells for AAV8-doubleY-F+T-V).
Tropism of AAV transduction in the ENS
Next we wanted to determine what type of cells AAV was able to 
transduce within the ENS. Similar to the CNS, the ENS is com-
posed mainly of neurons and glial cells.1,2,8 To determine the phe-
notype of transduced cells, colonic tissue showing GFP-positive 
cells was stained for HUc, and also glial fibrillary acidic protein 
Figure 4 Neuronal tropism of recombinant adeno-associated virus (AAV) transduction in the submucosal plexus (SMP): serotypes 1, 2, 5, 6, 
8, and 9. Adult male rats received direct injections of AAV (6 × 5 µl injections at 1.3 × 1012 vg/ml) into the wall of the descending colon and were sac-
rificed one month later, at which time the SMP was dissected. SMP tissue was stained for the neuronal marker HUc (red) and the enteric glia marker, 
glial fibrillary acidic protein (GFAP; blue). Following, the SMP was viewed under a fluorescent microscope and the transduction of neurons in the SMP 
was determined by examining the colocalization of green fluorescent protein (GFP; green) expression in HUc-positive cells (colocalization appears in 
yellow). Neuronal transduction was observed for all serotypes examined. Representative images of neuronal transduction are shown for AAV1 (a–d), 
AAV2 (e–h), AAV5 (i–l), AAV6 (m–p), AAV8 (q–t), and AAV9 (u–x). Scale bar in (x) represents 100 µm and applies to panels (a–w).
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(GFAP), a protein expressed in enteric glia. Similar to results 
observed in the CNS when using the same expression cassette, 
the vast majority of transduction mediated by all serotypes tested 
(with the exception of AAV6) was neuronal.2,4,23,24 The MP exists 
in a relatively flat plane containing two-dimensional clusters of 
disc like neurons (Figure 3 HUc; red), which are closely bundled 
by intraganglionic enteric glia (Figure 3 GFAP; blue) along the 
edges of neurons. Transduction of neurons in the MP was seen in 
soma (Figure 3a,e,i,m,q,u) as well as the fibers tracts connecting 
ganglia (Figure 3a,i,m).
Neuronal transduction was also observed in the SMP 
(Figure  4). Unlike the MP, neurons within the SMP appear as 
grape-like clustered that are sheathed in supportive intragangli-
onic enteric glia (see Figure 4b–d). Transduction appeared within 
soma (Figure 4a,e,i,m,q,u) as well as neuronal fibers (Figure 
4q,u), however GFP-positive fibers in the SMP were not as abun-
dant or intense as in the MP.
Similar to their WT counterparts, the AAV2 and 8 cap-
sid mutants showed a highly neuronal tropism that was con-
sistent across the MP (Supplementary Figure S3) and SMP 
(Supplementary Figure S4). We did not observe any changes in 
tropism produced by these capsid mutations.
Certain serotypes exhibited an exclusively neuronal tropism 
while others had a much more promiscuous tropism, showing 
Figure 5 Glial tropism of recombinant adeno-associated virus (AAV) transduction. Adult male rats received direct injections of AAV (6 × 5 µl injec-
tions at 1.3 × 1012 vg/ml) into the wall of the descending colon and were sacrificed one month later, at which time the submucosal plexus (SMP) and 
myenteric plexus (MP) were dissected. MP and SMP tissue was stained for the enteric glia marker, glial fibrillary acidic protein (GFAP; blue). Following, 
tissue was viewed under a fluorescent microscope and the transduction of glia was determined by examining the colocalization of green fluorescent 
protein (GFP; green) expression in GFAP-positive enteric glia (colocalization appears turquoise). Micrographs also show the neuronal marker HUc 
(red). Glia transduction was rare and was only observed in AAV serotypes 1, 5, 6, 8 and AAV8-doubleY-F+T-V. AAV6 showed far more glial transduction 
than any other serotype. Morphologically, most glial transduction appeared to occur within reactive, protoplasmic or mucosal, enteric glia (d,h,p, 
and t). In contrast, AAV6 was able to transduce intraganglionic enteric glia (l). Representative images of glial transduction are shown for AAV1 in 
the MP (a–d), AAV5 in the MP (e–h), AAV6 in the SMP (i–l), AAV8 in the SMP (m–p), and AAV8-doubleY-F+T-V in the SMP (q–t). Scale bar in (d,t) 
represents 50 µm and applies to (a–c) and (q–s). Scale bars in (h,l,p) represent 100 µm and apply to (e–g,i–k,m–o).
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GFP expression within neurons as well as enteric glia. For exam-
ple, AAV2 (Figures 3e–h and 4e–h) and AAV9 (Figures 3u–x and 
4u–x) exhibited an almost purely neuronal tropism. In contrast, 
AAV serotypes 1, 5, 6, 8 and AAV8-doubleY-F+T-V, showed both 
neuronal and glial transduction (Figure 5). It should be noted that 
in most instances glial transduction was proportionally secondary 
to neuronal transduction. However, special note should be paid to 
AAV6, which exhibited a tropism that was roughly equal between 
neurons and glia (Figure 5i–l). Further, a qualitative assess-
ment of glial morphology suggested that the majority of glial 
transduction observed with other serotypes seemed to be taking 
place within reactive “protoplasmic” or “mucosal” enteric glia 
(Figure 5d,h,p,t). In contrast, while AAV6 also showed expres-
sion within reactive glia, it also transduced the structural intra-
ganglionic enteric glia. This is well demonstrated in Figure 5i–l.
Time course and titer response of AAV9 transduction 
in the ENS
The ability of AAV to transduce cells of the ENS could have 
important implications to both model as well as potentially treat 
Figure 6 Time course and titer response of recombinant adeno-associated virus (AAV) serotype 9 in the myenteric plexus (MP) and submuco-
sal plexus (SMP) of the enteric nervous system. Time course (a–h): Adult male rats received direct injections of high titer AAV9 (6 × 5 µl injections 
at 1.2 × 1013 vg/ml) into the wall of the descending colon and were sacrificed 2, 4, or 6 weeks postsurgery, at which time the MP and SMP were 
dissected and viewed under a fluorescent microscope. Transduction efficiency of the 2-week (a, dark blue columns), 4-week (a, light blue columns), 
and 6-week groups (a, turquoise columns) was measured by the quantification of green fluorescent protein (GFP) expressing cells in the MP (a, left 
column grouping) and SMP (a, right column grouping). Columns represent mean number of GFP-positive cells, expressed as cells/mm2, + 1 SEM (n 
= 4–6/group). The 4- and 6-week groups had significantly more GFP-positive cells in both the MP and SMP than the 2-week group. No difference 
between the 4- and 6-week groups was observed. (b) The percent of HUc-positive cells expressing GFP ± SEM (n = 4–6/group). Representative images 
of GFP (green) and HUc (red) positive cells are shown for the 2-week (c), 4-week (d), and 6-week (e) group in the MP and the 2-week (f), 4-week (g), 
and 6-week (h) groups in the SMP. * Indicates significantly different than AAV9 at 2 weeks (P < 0.05). Titer response (i–p): Adult male rats received 
direct injections of AAV9 at a low titer (6 × 5 µl injections at 1.3 × 1012 vg/ml), an intermediate titer (6 × 5 µl injection at 6.25 × 1012 vg/ml) or a high 
titer (6 × 5 µl injections at 1.2 × 1013 vg/ml) into the wall of the descending colon and were sacrificed 1 month later, at which time the MP and SMP 
were dissected and viewed under a fluorescent microscope. Transduction efficiency of low-titer AAV9 (i, dark blue columns), intermediate titer AAV9 
(i, light blue columns) and high-titer AAV9 (i, turquoise columns), were measured by the quantification of green fluorescent protein (GFP) expressing 
cells in the MP (i, left column grouping) and SMP (i, right column grouping). Columns represent mean number of GFP-positive cells, expressed as 
cells/mm2, + 1 SEM (n = 4–6/group). The intermediate (6.25 × 1012) and high titer (1.2 × 1013) AAV9 groups had significantly more GFP-positive cells 
in both the MP and SMP than the low titer (1.3 × 1012) AAV9 groups. (j) The percent of HUc-positive cells expressing GFP ± SEM (n = 4–6/group). 
Representative images of GFP (green) and HUc (red) positive cells are shown for the low titer (k), intermediate titer (l), and high titer (m) groups in 
the MP and the low titer (n), intermediate titer (o), and high titer (p) groups in the SMP. * Indicates significantly different than AAV9 at 1.2 × 1012 vg/
ml (P < 0.05). Scale bar in (h and g) represents 100 µm and applies to all panels.
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disorders of the ENS. However, the level of transduction observed 
in our initial experiments was modest, which was not surpris-
ing given the relatively low titer utilized. Thus, we next wanted to 
determine if AAV transduction in the ENS could be increased in a 
titer-dependent manner, as well as to determine the optimal time 
postinjection needed for maximal transduction. In our initial 
experiments, AAV9 showed high levels of transduction and the 
most consistent neuronal transduction profile, thus we chose to 
perform a thorough characterization of the time course and titer 
response of AAV9 in both the MP and SMP.
To characterize the time course of AAV9 transduction, adult 
rats received identical injection of AAV9-GFP at a high titer of 
1.2 × 1013 and GFP-positive cells were quantified in the MP and 
SMP at 2, 4, and 6 weeks postsurgery. Within both the MP and 
SMP, there was a significant increase in the number of GFP-
positive cells/mm2 from 2 weeks (25.9 ± 5.2 cells/mm2 in the 
MP; Figure 6a,c; and 16 ± 2 cells/mm2 in the SMP; Figure 6a,f) 
to 4 weeks postsurgery (51.8 ± 5.9 in the MP; Figure 6a,d; and 
26.8 ± 0.9 cells/mm2 in the SMP, Figure 6a,g). The percent of 
HUc-positive cells transduced also increased from the 2 weeks 
postsurgery (28.9 ± 3.6% in the MP; Figure 6b,c; and 61.2 ± 2.7% 
in the SMP; Figure 6b,f) to 4 weeks postsurgery (75.5 ± 0.7% in 
the MP; Figure 6b,d; and 93 ± 0.7% in the SMP, Figure 6b,g). The 
level of transduction plateaued at 4 weeks postsurgery and there 
was no increase in transduction from 4 to 6 weeks postsurgery 
in either the MP (50.6 ± 6.5 cells/mm2 and 72.4 ± 3.7% of HUc-
positive cells; Figure 6a,b,e) or SMP (23 ± 1.6 cells/mm2 and 
87.9 ± 2.7% of HUc-positive cells; Figure 6a,b,h).
For the titer response, adult rats received identical injections 
of AAV9 at either the initial titer of 1.3 × 1012 vg/ml, an interme-
diate titer of 6.25 × 1012 vg/ml, or the high titer of 1.2 × 1013 vg/
ml, and transduction in the MP and SMP was compared 1 month 
(when AAV9 reaches maximal expression in the MP and SMP) 
following surgery. As can be seen in Figure 6i, the intermedi-
ate titer of 6.25 × 1012 significantly increased transduction in the 
ENS compared to the low-titer group. AAV9 at 6.25 × 1012 pro-
duced an approximate fivefold increase in the number of GFP-
positive cells in both the MP (59.3 ± 18.2 cells/mm2; Figure 6i,l) 
Figure 7 The spread of a single injection of recombinant adeno-associated virus (AAV) serotype 9 in the myenteric plexus (MP) and submu-
cosal plexus (SMP) of the enteric nervous system. Adult male rats received direct injections of AAV9 (1.2 × 1013 vg/ml) into the wall of the descend-
ing colon and were sacrificed one month later, at which time the MP and SMP were dissected and viewed under a fluorescent microscope. The 
spread of transduction was determined by quantifying the area of the MP and SMP containing green fluorescent protein (GFP)-positive cells. Panel 
(a) and (b) show representative images of vector spread and transduction following a single injection of AAV9 within the MP and SMP, respectively. 
Representative images are shown with axis to indicate longitudinal (x-axis) and perpendicular (y-axis) spread. Tick marks on the axis represent 1 mm. 
The circle in the center of the axis represents the approximate location of the injection site. Insets represent high magnification images of the area 
within the white box in a and b. Scale bars in (a) and (b) represent 1 mm. Scale bars in the insets in (a) and (b) represent 50 µm.
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and the SMP (23.9 ± 4.7 cells/mm2; Figure 6i,o) over the lower 
titer injection (values given above; Figure 6i,k,n). The intermedi-
ate titer of 6.25 × 1012 also produced a significant increase in the 
percent of HUc-positive cells transduced in the MP (65.6 ± 0.7%; 
Figure 6j,l) and SMP (77.9% ± 9.9; Figure 6j,o) as compared to 
the low titer of 1.3 × 1012 (values given above; Figure 6j,k,n). The 
high titer of 1.2 × 1013 did not result in an increase in transduc-
tion over the intermediate titer group in either the MP (52.9 ± 10.1 
cells/mm2 and 75.5 ± 0.7% of HUc-positive cells; Figure 6i,j,m) or 
SMP (23.1 ± 0.8 cells/mm2 and 86.1 ± 2.1% of HUc-positive cells; 
Figure 6i,j,p) suggesting a plateau in the number of transduced 
cells possible. In support of this notion, qPCR quantification of 
the relative changes in viral genome concentrations between treat-
ment groups showed a titer-dependent increase in viral genomes 
detected from the low titer (2∆∆Ct of 5.7 ± 0.9 in the MP and 
3.9 ± 0.2 in the SMP; Supplementary Figure S5), to the interme-
diate titer (2∆∆Ct of 18.7 ± 1.9 in the MP and 16.2 ± 4.3 in the SMP; 
Supplementary Figure S5), to high-titer group (2∆∆Ct of 72.5 ± 2.8 
in the MP and 63.7 ± 3.9 in the SMP; Supplementary Figure S5), 
despite the absence of a corresponding increase in the number of 
cells/mm2 or the percent of HUc-positive cells transduced (Figure 
6i,j), implicating a saturation effect.
Spread of AAV transduction in the ENS
Future work will be aimed at modulating GI function using AAV-
mediated gene delivery, thus, in the initial portion of this study, 
we aimed to target a relatively large portion of the colon (six injec-
tions spread out over ~1.5 cm2 of the descending colon). However, 
to better understand the area of transduction that can be achieved 
by the current surgical administration, we also aimed to evalu-
ate the spread of transduction following a single injection of AAV 
into the descending colon. Adult rats received a single injection 
of AAV9 (5 μl, 1.2 × 1013vg/ml) into the wall of the descending 
colon and 1-month postsurgery the spread of transduction from 
the injection site was quantified. Following a single injection, the 
area containing GFP-positive cells was ~47.2 ± 1.8 mm2 in the MP 
and 46.6 ± 5.5 mm2 in the SMP. These values were back-calculated 
to correspond to the area of transduction within the unprocessed 
colon and thus represent the degree of spread that would be 
expected within an intact colon in vivo. Figure 7 shows represen-
tative images of transduction spread following a single injection 
in the MP (Figure 7a) and the SMP (Figure 7b). The circle at the 
center of the axis represents the approximate location of the injec-
tion site. The majority of spread occurred along the longitudinal 
plane (oral to anal) of the ENS (Figure 7a,b, x-axis), although 
there was still a large amount of spread long the perpendicular 
plane (Figure 7a,b, y-axis).
In addition to measuring the spread of transduction following 
a single injection within the ENS, we also wanted to monitor any 
spread of transduction outside of the ENS. Vagal and sacral spi-
nal parasympathetic nerves directly innervate the colon, and this 
innervation could serve as a potential route for spread of trans-
duction outside of the ENS, possibly to the CNS. Accordingly, we 
monitored for transduction in the dorsal motor nucleus of the 
vagus and the lumbar/sacral region of the spinal cord following 
injection of AAV9 (6 × 5 μl, 1.2 × 1013 vg/ml) into the descend-
ing colon. We detected no GFP-positive cells (data not shown) or 
viral genomes within either region (Supplementary Figure S5), 
suggesting that the observed transduction is limited to the area 
immediately surrounding the targeted ENS. In line with this, we 
did detect some GFP-positive cells within the smooth muscle of 
the injected gut wall, however the number of transduced smooth 
muscle cells was far lower compared to that observed within the 
ENS (data not shown). No transduction was observed in the 
mucosa of the injected colon.
Systemically delivered AAV readily transduces a multitude 
of organs throughout the body.4,6,25,26 In order to address whether 
our surgical approach would result in viral particles in circula-
tion, we also measured viral genomes of the liver and the spleen 
but detected no increase in genomes over naive control animals 
(Supplementary Figure S5).
Surgical adaptation
Many GI disorders are segmental in nature and localize to a spe-
cific area along the GI tract. Thus, we wanted to adapt the sur-
gical delivery of AAV to other discrete areas along the GI tract. 
Adaptation of the surgical delivery was tested by performing a 
single injection of AAV9 (5 μl, 1.2 × 1013 vg/ml) directly into the 
wall of the small intestine, the cecum or the ascending colon of 
adult rats, and 1 month later the presence of GFP-positive cells 
in the ENS of the respective areas was probed. AAV9 transduced 
large networks of ganglia within the approximate area of the ileo-
jejunual boundary within the small intestine (Supplementary 
Figure S6a,b). Further, targeted delivery of AAV9 transduced 
neurons in the cecum (Supplementary Figure S6c), and ascend-
ing colon (Supplementary Figure S6d), in a similar pattern to 
that observed in the descending colon.
We also wanted to translate our approach across species. The 
mouse is a commonly used organism to study GI function and 
many physiological analyses of GI function are performed in this 
species. As such, the ability of direct administration of AAV to 
transduce the murine ENS was analyzed. AAV9 (6 × 2 μl, 1.2 × 1013 
vg/ml) was injected directly into the wall of the descending colon of 
adult mice, and 1 month later the presence of GFP-positive cells in 
the ENS was probed. Supplementary Figure S6 demonstrates the 
ability of AAV9 to transduce neurons of the MP (Supplementary 
Figure S6e) and the SMP (Supplementary Figure S6f) within the 
mouse ENS, validating the ability to translate this approach across 
species.
Characterization of local inflammation in the ENS 
following AAV delivery
One limiting factor associated with viral vector-based gene ther-
apy is the potential to elicit an immune response. In order to 
determine if the direct administration of AAV to the ENS results 
in an increase in local inflammation, immunohistochemical char-
acterization of cells expressing ionized calcium-binding adapter 
molecule 1 (IBA1) was performed. IBA1 is a protein specific to 
macrophages and microglia, and is a common marker for neu-
roinflammation.4,27 Although IBA1-positive cells are normally 
observed within neural tissue, an increase in IBA1-positive cell 
number, concurrent with morphological changes, is indicative of 
inflammation.5,6,28 IBA1-positive cell numbers were quantified in 
the MP and SMP taken from representative AAV injected animals, 
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which showed successful transduction. Additionally, we analyzed 
changes in IBA1 cell numbers in animals injected with saline 
(control for vector administration), the proinflammatory endo-
toxin lipopolysacchride (LPS; 6 × 5 μl, 1mg/ml; positive control), 
and animals that remained naïve to surgery (control for surgery).
Direct injection of LPS into the colon resulted in a significant 
increase in IBA1-positive cells in both the MP (Supplementary 
Figure S7a,e) and the SMP (Supplementary Figure S7b,s). 
Animals receiving injections of saline had similar numbers of 
IBA1-positive cells as naive animals (Supplementary Figure 
S7a–d,q,r). Finally, there were no significant changes in IBA1-
positive cell numbers associated with any of the AAV serotypes 
tested (Supplementary Figure S7a,b).
In addition to quantifying changes in IBA1-positive cell 
numbers, we also performed a qualitative morphological assess-
ment of IBA1-positive cells in all experimental groups. Resting 
macrophages are morphologically characterized by multiple pro-
cesses extending from the soma in what is termed a “ramified” 
state.8,29 Following an inflammatory stimulus, activated macro-
phage will begin to retract processes and take on a more amoe-
boid morphology.9,29 In general, it appeared that IBA1-positive 
cells in the MP (Supplementary Figure S7c,d,f–p) more closely 
resembled resting macrophages than IBA1-positive cells in the 
SMP (Supplementary Figure S7q,r, T-DD), which seemed to 
have a rounder soma with shorter processes. LPS administration 
resulted in the appearance of amoeboid IBA1-positive cells, char-
acteristic of local inflammation (Supplementary Figure S7e,s). 
In contrast, the noninjected animals showed IBA1-positive cells 
with long processes extending from a thin soma (Supplementary 
Figure S7c,q). There did not appear to be any large differences 
between the morphology of IBA1-positive cells between the 
noninjected and saline-treated animals, nor any of the serotypes 
tested within either the MP (Supplementary Figure S7c,d,f–p) or 
SMP (Supplementary Figure S7q,r, T-DD).
DISCUSSION
The use of AAV vectors to manipulate gene expression in vari-
ous cell types within both central and peripheral tissue has been 
extensively characterized. However, to date, there are no reports 
on the targeted ability of AAV to transduce cells of the ENS within 
an adult animal. The work presented herein provides the first 
detailed description of the targeted use of AAV vectors to trans-
duce both neurons and glia of the MP and SMP within delineated 
areas of the ENS.
One basic consideration when utilizing vector-based gene 
therapy is the optimal mode of gene delivery. Although systemic 
or peroral delivery of AAV has been shown to access the gut, these 
delivery methods must overcome significant barriers to achieve 
successful transduction, and dramatically increase the risk of off-
target effects. For example, peroral administration of AAV can 
transduce cells of the gut mucosa, however via this route, AAV 
failed to transit the blood–gut epithelia barrier and transduce 
cells of the ENS.5,10–13,30 Conversely, systemically delivered AAV 
can transit the blood–gut barrier, but will cross the blood–brain 
barrier and transduce cells of the CNS, as well as a wide range 
of other nontarget organ tissues throughout the body.6,14,26,31,32 In 
contrast, using the method detailed herein, we did not observe 
any increase in viral genomes in any other tissues sampled, dem-
onstrating highly efficient transduction that is limited to a discrete 
area of the ENS. By using direct injections of AAV into the wall of 
the descending colon, we were able to achieve transgene expres-
sion within both the MP and SMP within weeks after surgery. This 
approach allows for both spatial and temporal control of gene 
expression and could be further strengthened by the use of cell 
specific promoters in order to achieve transduction within a phe-
notypically distinct cell type; e.g., cholinergic neurons.
The approach used in the current study provides a unique 
platform upon which to model or treat ENS disorders. Due to the 
myriad of functions the ENS facilitates, and the severe ramifica-
tions of ENS dysfunction, it is becoming increasingly necessary 
to understand the physiology of the ENS in health and disease. 
The ability to manipulate gene expression specifically within the 
ENS obviates any off target effects that may arise when using the 
transgenic or psychological stress-based models that are currently 
used to study ENS disorders.14–17 Moreover, targeted injections 
effectively circumvent any confound that may arise due to trans-
duction of the brain or spinal cord following systemic injections. 
Additionally, we have shown that transduction of the ENS could 
also be achieved in both rat and mouse. Many of the physiological 
endpoints used to study ENS and GI function are performed in 
the mouse, and as such, the ability to manipulate gene expression 
within the murine ENS will undoubtedly prove to be an invaluable 
research tool. Further, this site-specific surgical approach enables 
transduction of a discrete functional unit within the ENS. Due to 
the fact that many disorders of the ENS localize to distinct areas 
along the GI tract, it is likely that this use of highly specific sur-
gical injection of AAV will pave the way for model systems that 
more accurately recapitulate disorders of the ENS.
The level of transgene expression achieved by AAV is depen-
dent upon the serotype, the expression cassette, and the target 
tissue. Here we aimed to determine the relative transduction 
efficiencies of various AAV serotypes within the cells of the ENS. 
AAV1 and AAV2 consistently showed very low levels of expres-
sion while AAV6 and AAV9 showed relatively high levels of 
expression. The increased transduction efficiency of AAV6 and 
AAV9 over other serotypes in the ENS is likely an effect of cap-
sid interactions with cognate receptors. For example, the unique 
transduction efficiency and tropism of AAV6 may be due to a spe-
cific surface-exposed lysine residue. There are only six amino acid 
differences between AAV1 and AAV6, and of these, lysine 531 is 
responsible for the increased receptor binding, transduction effi-
ciency and peripheral tropism of AAV6.33,34 Similarly, the unique 
ability of AAV9 to penetrate epithelial barriers is thought to be 
mediated by a specific interaction with a unique receptor popu-
lation.19,20,31,32 Accordingly, the differential transduction efficien-
cies of the serotypes tested herein are indicative of unique capsid 
interaction with specific receptors in the ENS that favor AAV6 
and AAV9.
Beyond transduction efficacy, we also sought to determine 
the tropism of the AAV serotypes tested. The ENS is composed 
of cells of both neuronal and glial lineage. All serotypes tested 
displayed at least some neuronal tropism. However, the fidelity of 
neuronal tropism varied, with some serotypes exhibiting almost 
purely neuronal transduction (e.g., AAV 2, 9) and others showing 
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promiscuous tropism, transducing both neurons and glia (e.g., 
AAV6). AAV6 was remarkable in terms of glial tropism. AAV6 
transduction of ENS glia could be seen in both reactive enteric 
glia as well as the structural intraganglionic glia, which compose 
a piece of the ganglionic infrastructure. Differential tropism of 
AAV6 as compared to other serotypes has been observed previ-
ously in other tissue such as liver, heart, and specific subregions 
of the CNS,26,34–36 and may be a unique characteristic of the AAV6 
capsid (e.g., lysine 531). The impressive ability of AAV6 to trans-
duce both glia and neurons, likely explains the high transduction 
efficiency of this serotype in this study. This non-neuronal trans-
duction observed was rather surprising, however, as this event is 
relatively infrequent in the brain using the same viral genome and 
serotypes as utilized here.23
Within the current work AAV9 produced high levels of 
transduction with the most consistent neuronal tropism, thus, 
we sought to optimize the titer and time post-surgery necessary 
to produce the highest levels of transgene expression. AAV9 
reached maximal transgene expression at 4 weeks, and at this 
4-week time point AAV9-mediated transduction in both the 
MP and SMP plateaued at a titer of 6.25 × 1012 vg/ml. Although 
increasing titers beyond 6.25 × 1012 vg/ml increased the relative 
concentrations of AAV genomes detected within the injected 
area of the ENS, the percentage and number of neurons trans-
duced remained constant at ~75% in the MP and 85% in the 
SMP, suggesting a ceiling effect in the number of neurons capa-
ble of being transduced. Indeed, in work by Gombash et al. 7, a 
slightly lower percentage of neuronal transduction was observed 
in the MP of neonatal mice after systemic delivery of AAV9. 
Within this work, it was demonstrated that excitatory, sensory, 
and ascending projection neurons were preferentially trans-
duced, suggesting that an inability to transduce certain func-
tional groups of neurons of the ENS, such as inhibitory neurons, 
is a possible limiting factor in the amount of transduction pos-
sible. Regardless, the fact that we observed an increase in viral 
genomes suggests that transgene expression can be increased 
using titers greater than 6.25 × 1012 vg/ml. This may be valuable 
when evaluating the titer-response to a certain gene, or when 
large amounts of gene-product are required.
Finally, a note must be made on the AAV-induced inflamma-
tion in the ENS. One inherent limitation to viral vector-based gene 
therapy is the potential to elicit an immune response. Injection of 
AAV can result in a humoral response, and the production of neu-
tralizing antibodies, or a cell-mediated immune response and the 
destruction of virally infected host cells,37 and as such represents a 
major obstacle that must be carefully monitored. Here, we moni-
tored the initiation of a local immune response by examining the 
numbers and morphology of IBA1-positive cells within the trans-
duced ENS. We found no increases in IBA1-positive cells in any of 
the AAV-injected animals. Further, the majority of IBA1-positive 
cells observed seemed to be in the “ramified” state, a morphology 
associated with inactive macrophages.29 However, IBA1-positive 
cell numbers and morphology is a cursory analysis that is limited 
to local inflammation and yields no insight into a virally initiated 
humoral response. As such, future studies will aim to provide a 
more detailed analysis of any potential immune response by the 
targeted delivery of AAV to the ENS.
CONCLUSION
We have shown that targeted delivery of AAV vectors can suc-
cessfully transduce cells of the ENS. Transduction was observed 
in both neurons and glia in the MP and the SMP. A comparison 
across serotypes revealed that AAV6 and AAV9 showed the high-
est levels of transduction. We observed differential tropism based 
upon the serotype being used, with AAV9 primarily transducing 
neurons and AAV6 transducing neurons and glia. Transduction 
efficiency of AAV9 scaled with titer and time, and plateaued at 
4 weeks postsurgery with a titer of 6.25 × 1012 vg/ml. Infection pro-
duced little to no local immune response specific to the vector. The 
spread from a single, targeted injection of AAV9 into the descend-
ing colon covered an area of ~47 mm2 and no viral genomes were 
detected in other tissues. Finally, the targeted application of AAV 
was also translated to the small intestine, the proximal colon, and 
the murine ENS. To our knowledge, this is the first detailed report 
on the ability of targeted AAV delivery to transduce both neurons 
and glia within predefined areas of the ENS of an adult animal. 
This study illustrates that various AAV serotypes can be used to 
successfully transduce relatively specific cell types within discrete 
regions of the ENS, opening the door for the creation of more 
accurate models of ENS dysfunction as well as the potential for 
the development of therapeutic applications.
MATERIALS AND METHODS
AAV vector construction. AAV vectors encoding humanized GFP under 
control of the hybrid chicken β-actin/cytomegalovirus promoter were pro-
duced as described previously.33 Briefly, viruses were created by cotrans-
fection of the AAV transgene plasmids with a helper plasmid encoding 
capsid proteins for serotypes AAV1, AAV2, AAV5, AAV6, AAV8, or AAV9. 
Subsets of AAV2- and AAV8-based vectors were produced by cotransfec-
tion with respective helper plasmids encoding capsids containing point 
mutations of surface exposed tyrosine residues (tyrosine to phenylala-
nine, Y-F). These included AAV2-Y444F, AAV2-Y444F+Y500F+Y703F 
(referred to as AAV2-tripleY-F), and AAV8-Y733F.19,20 An additional 
subset of vectors tested contained a combination of Y-F and threonine-
valine (T-V) capsid mutations These included AAV2-tripleY-F+T491V 
(referred to as AAV2-tripleY-F+T-V) and AAV8-Y447F+Y733F+T494V 
(referred to as AAV8-doubleY-F+T-V).18,22 These capsid mutants exhibit 
increased transduction efficiency in other tissues.18–22 Following transfec-
tion, cells were harvested and lysed, and virus was purified as described 
previously.33,38 Virus titers were determined using dot blot assays33 and all 
viral preparations were normalized to 1.3 × 1012 viral genomes per millili-
ter (vg/ml) using balanced salt solution (Alcon Laboratories, Fort Worth, 
TX), with the exception of the high titer AAV9, which was normalized to 
1.2 × 1013 vg/ml.
Animals and surgery. Experiments were conducted on young adult 
(220 g) male Sprague Dawley rats or young adult (30 g) C57Bl/6j mice in 
accordance with guidelines of the Michigan State University Institutional 
Animal Care & Use Committee (AUF 08/12-150-00). Rats were housed 
two per cage, while mice were housed four to five per cage, and maintained 
in a light-controlled (12 hours light/dark cycle; lights on 06:00 hours) and 
temperature-controlled (22 ± 1 °C) room, and provided with food and tap 
water ad libitum.
All surgery was performed under 2% isofluorane anesthesia. The 
surgical site was shaved and scrubbed with betadine. A vertical incision 
was made in the abdomen from the level of the pelvis to the sternum. 
The abdominal wall was resected exposing the peritoneal cavity after 
which the descending colon was exposed. A small horizontal tattoo 
(AIMS tattoo ink) was placed midway down the descending branch of 
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the colon in order to mark the injection site. Following, rats received 
6 × 5 μl injections, and mice received 6 × 2 μl injections, of AAV applied 
in a 2 × 3 injection grid distal to the tattoo. Initial experiments were 
performed in order to optimize the delivery parameters of AAV to the 
ENS (Supplementary Table S1) and the final optimized parameters are 
described below. The number and volume of injections was chosen to 
ensure that the spread of virus covered an area large enough to allow for 
analyses of transduction efficiency and tropism. A subset of rats received 
a single 5 μl injection in order to determine the degree of vector spread 
achieved from a single injection and demonstrate transduction in distinct 
regions of the ENS. Injections into the wall of the descending colon were 
made horizontally to the longitudinal axis of the colon, with the bevel 
of the needle resting in between the muscle layers, just below the level 
of the tattoo, using a siliconized (sigmacote, Sigma, St. Louis, MO) 50 
µl Hamilton syringe with a 22 gauge (rat) or 31 gauge (mouse) beveled 
needle, connected to a Harvard Apparatus foot operated pump. AAV was 
injected at a flow rate of 10 μl/minute in order to enhance convection, and 
afterward the needle was left in place for 1 minute to prevent reflux.
Following injections, the contents of the peritoneal cavity were put back 
in place, the abdominal wall was sutured and the overlying skin was stapled 
closed. Animals were given an injection of timentin (60 mg/kg; i.p.) and 
ketofen (5 mg/kg; i.p.) in order to prevent infection and reduce discomfort. 
Animals were monitored postoperatively for signs of distress or infection.
Tissue collection. At the time of sacrifice, animals received a lethal injection 
of sodium pentobarbital and were transcardially perfused with 0.9% sterile 
saline. Brains and spinal cords were rapidly removed and postfixed in 4% 
paraformaldehyde in phosphate-buffered saline (PBS) for 3 days. The liver 
and spleen was removed and immediately frozen. The descending colon 
(cut ~1 cm above and 2 cm below the level of the tattoo) was collected. After 
removal from the animal, the collected colon tissue was cut along the lon-
gitudinal axis, stretched, and pinned out on a gelatin-coated petri dish. The 
colon tissue was then washed three times with PBS and postfixed in 4% para-
formaldehyde in PBS for 24 hours. The descending colon tissue (at the level 
of the injection) was cut into 0.5 cm2 sections. The submucosal plexus and 
myenteric plexus was then dissected from these sections under a dissecting 
microscope and stored in TBS at 4 °C until further histological processing.
Immunohistochemistry. For colonic tissue, immunohistochemistry was 
performed on free floating sections containing the submucosal and myen-
teric plexus, respectively. Sections were washed in 1× TBS containing 0.25% 
Triton x-100, blocked in 10% serum (specific to the secondary antibody) 
and incubated for 3 days in primary antibody at 4 °C. Primary antibod-
ies used were rabbit anti-GFP (Abcam; ab290, Cambridge, MA), chicken 
anti-GFAP (Abcam; ab4674), mouse anti-HUc/HUd (Life Technologies; 
A21271), rabbit anti-IBA1 (Wako; PDF3116, Richmond, VA). Secondary 
antibodies used were Goat anti-mouse alexafluor 594 (Life Technologies; 
A11005), goat anti-rabbit alexafluor 488 (Life Technologies; A11008, 
Carlsbad, CA), donkey anti-chicken IRDye 680LT (LiCor; 926–68028, 
Lincoln, NE). Sections were then washed in TBS and covered slipped using 
vectashield hard set mounting medium.
For brain tissue and spinal cords, tissues were frozen on dry ice 
and coronal sections (40 μm) were cut through the rostrocaudal axis of 
the brain using a sliding stage microtome. Immunohistochemistry was 
performed on free-floating sections. Sections were washed in 1× TBS 
containing 0.25% Triton x-100, blocked in 10% normal goat serum 
and incubated overnight in rabbit anti-GFP (Abcam; ab290) primary 
antibody at 4 °C. Sections were then washed and incubated in biotin-
conjugated goat anti-rabbit (Millipore; AP132B, Billerica, MA), followed 
by 2 hours in ABC solution (Vector Labs Burlingame, CA). Sections were 
then incubated in diaminobenzidine (50 mg/100 ml with 0.03% hydrogen 
peroxide). Finally, sections were washed in TBS and covered slipped using 
cytoseal mounting medium (Thermo scientific, Kalamazoo, MI.).
Tissue was viewed on a Nikon eclipse 90i fluorescence microscope 
connected to a Q-imaging fast 1394 camera.
Cell counts. GFP-positive cell counts were performed as previously 
described.39 Briefly, tissue collected from the same location relative to the 
tattoo for all animals from each respective serotype grouping was analyzed. 
5 mm2 sections of tissue from an area immediate to the injection site as 
well as sections anterior and posterior to the injection site were viewed 
under a fluorescence microscope for native fluorescence of the reporter 
gene or immunofluorsecence of HUc-positive neurons, and images of the 
respective area of colon were acquired. The exposure time used to acquire 
all images was identical. GFP- and HUc-positive cell counts in the MP 
and SMP were performed from the acquired images. Following, GFP- 
and HUc-positive cell counts from the immediate, anterior, and posterior 
sections were pooled in order to get a total GFP- and HUc-positive cell 
number for all animals. Total GFP cell counts were then normalized to 
tissue area and expressed as cells/mm2 or represented as the percentage 
of HUc-positive neurons within the same counting area. Within initial 
experiments, there were some failed injection of AAV to the ENS and these 
animals were excluded from further analysis.
qPCR analysis of AAV genomes. Genomic DNA was extracted from the 
previously dissected MP and SMP by incubating tissue in extraction buffer 
(200 mmol/l tris, 250 mmol/l NaCl, 25 mmol/l ethylenediaminetetraacetic 
acid, 0.5% sodium dodecyl sulfate) with proteinase K and RNase A at 55 
°C followed by phenol/chloroform extraction and ethanol precipitation of 
the DNA. DNA concentration was determined using a Nanodrop. qPCR 
primers for the AAV genome (Integrated DNA technology, Coralville, 
IA) and glyceraldehyde 3-phosphate dehydrogenase (Applied Biosystems, 
Waltham, MA) were conjugated to a FAM or VIC reporter, respectively. 
All primers were ensured to produce a single product as assessed by melt 
curve analysis. Glyceraldehyde 3-phosphate dehydrogenase was used as 
the reference gene and detection was similar across treatment groups. 
Samples for PCR reactions were run in quadruplicate and averaged to give 
a single mean value per sample. Changes between treatment groups were 
analyzed by the differences in ∆Ct, which compares the Ct value of the AAV 
genome to that of the glyceraldehyde 3-phosphate dehydrogenase control 
gene. Data is presented as fold change over corresponding control tissue as 
determined by the ∆∆Ct, which represent the ∆Ct normalized to a calibra-
tor, in this case noninjected control tissue.
Statistical analysis. The experimenter was blind to all experimental con-
ditions during data collection and analysis. One-way analysis of variance 
tests were used to test for statistical significance between two or more 
groups with a single independent variable. A P value of less than or equal 
to 0.05 was considered statistically significant. If the analysis of variance 
revealed an interaction of statistical significance, post hoc analysis was fol-
lowed by between group comparisons using Tukey’s test.
SUPPLEMENTARY MATERIAL
Figure S1. Transduction efficiency of recombinant adeno-associated 
virus (AAV) serotype 2 capsid mutants in the myenteric plexus (MP) 
and submucosal plexus (SMP) of the enteric nervous system.
Figure S2. Transduction efficiency of recombinant adeno-associated 
virus (AAV) serotype 8 capsid mutants in the myenteric plexus (MP) 
and submucosal plexus (SMP) of the enteric nervous system.
Figure S3. Neuronal tropism of recombinant adeno-associated virus 
(AAV) transduction in the myenteric plexus (MP): AAV serotypes 2 and 
8 capsid mutants.
Figure S4. Neuronal tropism of recombinant adeno-associated virus 
(AAV) transduction in the submucosal plexus (SMP): AAV serotypes 2 
and 8 capsid mutants.
Figure S5. Quantification of AAV spread and titer-dependent 
changes in viral genomes within the myenteric plexus (MP) and sub-
mucosal plexus (SMP).
Figure S6. Targeted delivery of AAV9 to the ENS within the rat small 
intestine, the rat proximal colon, and the mouse colon.
Figure S7. Local inflammation induced by the targeted delivery of 
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the recombinant adeno-associated virus (AAV) to the myenteric plexus 
(MP) anf submucosal plexes (SMP) of the enteric nervous system.
Table S1. Optimization of gene delivery to the enteric nervous system.
ACKNOWLEDGMENTS
This work was funded by the Michigan State University Foundation 
Strategic Partnership Grant. Special thanks to Xiachun Bian (Michigan 
State University) and Brian Gulbransen (Michigan State University) for 
training on dissections of the myenteric plexus and submucosal plexus 
from colonic tissue. 
REFERENCES
 1. Daya, S and Berns, KI (2008). Gene therapy using adeno-associated virus vectors. Clin 
Microbiol Rev 21: 583–593.
 2. Flotte, TR (2004). Gene therapy progress and prospects: recombinant adeno-
associated virus (rAAV) vectors. Gene Ther 11: 805–810.
 3. Mueller, C and Flotte, TR (2008). Clinical gene therapy using recombinant adeno-
associated virus vectors. Gene Ther 15: 858–863.
 4. Mingozzi, F and High, KA (2011). Therapeutic in vivo gene transfer for genetic disease 
using AAV: progress and challenges. Nat Rev Genet 12: 341–355.
 5. During, MJ, Xu, R, Young, D, Kaplitt, MG, Sherwin, RS and Leone, P (1998). Peroral 
gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med 
4: 1131–1135.
 6. Fu, H, Dirosario, J, Killedar, S, Zaraspe, K and McCarty, DM (2011). Correction of 
neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-
brain barrier gene delivery. Mol Ther 19: 1025–1033.
 7. Gombash, SE, Cowley, CJ, Fitzgerald, JA, Hall, JC, Mueller, C, Christofi, FL et al. (2014). 
Intravenous AAV9 efficiently transduces myenteric neurons in neonate and juvenile 
mice. Front Mol Neurosci 7: 81.
 8. Wood, JD. Enteric Nervous System (The-Brain-In-The-Gut). Morgan & Claypool Life 
Sciences, Princeton, NJ. 2011.
 9. Belkind-Gerson, J, Graeme-Cook, F and Winter, H (2006). Enteric nervous system 
disease and recovery, plasticity, and regeneration. J Pediatr Gastroenterol Nutr 42: 
343–350.
 10. Forsyth, CB, Shannon, KM, Kordower, JH, Voigt, RM, Shaikh, M, Jaglin, JA et al. 
(2011). Increased intestinal permeability correlates with sigmoid mucosa alpha-
synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS 
One 6: e28032.
 11. Braak, H, de Vos, RA, Bohl, J and Del Tredici, K (2006). Gastric alpha-synuclein 
immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for 
Parkinson’s disease-related brain pathology. Neurosci Lett 396: 67–72.
 12. Shannon, KM, Keshavarzian, A, Dodiya, HB, Jakate, S and Kordower, JH (2012). Is 
alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence 
from 3 cases. Mov Disord 27: 716–719.
 13. Shannon, KM, Keshavarzian, A, Mutlu, E, Dodiya, HB, Daian, D, Jaglin, JA et al. (2012). 
Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease. Mov 
Disord 27: 709–715.
 14. Mayer, EA and Collins, SM (2002). Evolving pathophysiologic models of functional 
gastrointestinal disorders. Gastroenterology 122: 2032–2048.
 15. Dawson, TM, Ko, HS and Dawson, VL (2010). Genetic animal models of Parkinson’s 
disease. Neuron 66: 646–661.
 16. Kanaan, NM and Manfredsson, FP (2012). Loss of functional alpha-synuclein: a toxic 
event in Parkinson’s disease? J Parkinsons Dis 2: 249–267.
 17. Kuhn, M, Haebig, K, Bonin, M, Ninkina, N, Buchman, VL, Poths, S et al. (2007). 
Whole genome expression analyses of single- and double-knock-out mice implicate 
partially overlapping functions of alpha- and gamma-synuclein. Neurogenetics 8: 
71–81.
 18. Kay, CN, Ryals, RC, Aslanidi, GV, Min, SH, Ruan, Q, Sun, J et al. (2013). Targeting 
photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS 
One 8: e62097.
 19. Petrs-Silva, H, Dinculescu, A, Li, Q, Min, SH, Chiodo, V, Pang, JJ et al. (2009). High-
efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. 
Mol Ther 17: 463–471.
 20. Petrs-Silva, H, Dinculescu, A, Li, Q, Deng, WT, Pang, JJ, Min, SH et al. (2011). Novel 
properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 19: 
293–301.
 21. Aslanidi, GV, River, AE, Ortiz, L, Song, L, Ling, C, Govindasamy, L et al. (2013). 
Small, N-terminal tags activate Parkin E3 ubiquitin ligase activity by disrupting its 
autoinhibited conformation. PLoS One 8: e59142–e59142.
 22. Gabriel, N, Hareendran, S, Sen, D, Gadkari, RA, Sudha, G, Selot, R et al. (2013). 
Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues 
improves its transduction efficiency in vitro and in vivo. Hum Gene Ther Methods 24: 
80–93.
 23. Burger, C. (2004). Recombinant AAV viral vectors pseudotyped with viral capsids from 
serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to 
different regions of the central nervous system. Mol Ther 10: 302–317.
 24. Reimsnider, S, Manfredsson, FP, Muzyczka, N and Mandel, RJ (2007). Time course of 
transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and 
rAAV2/8 transduction in the rat. Mol Ther 15: 1504–1511.
 25. Inagaki, K, Fuess, S, Storm, TA, Gibson, GA, Mctiernan, CF, Kay, MA et al. (2006). 
Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene 
transfer superior to that of AAV8. Mol Ther 14: 45–53.
 26. Zincarelli, C, Soltys, S, Rengo, G and Rabinowitz, JE (2008). Analysis of AAV serotypes 
1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 
16: 1073–1080.
 27. Ito, D, Tanaka, K, Suzuki, S, Dembo, T and Fukuuchi, Y (2001). Enhanced expression 
of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral 
ischemia in rat brain. Stroke 32: 1208–1215.
 28. Qin, L, Wu, X, Block, ML, Liu, Y, Breese, GR, Hong, JS et al. (2007). Systemic LPS 
causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 
453–462.
 29. Streit, WJ, Walter, SA and Pennell, NA (1999). Reactive microgliosis. Prog Neurobiol 57: 
563–581.
 30. During, MJ, Symes, CW, Lawlor, PA, Lin, J, Dunning, J, Fitzsimons, HL et al. (2000). 
An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. 
Science 287: 1453–1460.
 31. Manfredsson, FP, Rising, AC and Mandel, RJ (2009). AAV9: a potential blood-brain 
barrier buster. Mol Ther 17: 403–405.
 32. Foust, KD, Nurre, E, Montgomery, CL, Hernandez, A, Chan, CM and Kaspar, BK 
(2009). Intravascular AAV9 preferentially targets neonatal neurons and adult 
astrocytes. Nat Biotechnol 27: 59–65.
 33. Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr et al. (2002). 
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated 
viral vectors. Methods 28: 158–167.
 34. Wu, Z, Asokan, A, Grieger, JC, Govindasamy, L, Agbandje-McKenna, M and 
Samulski, RJ (2006). Single amino acid changes can influence titer, heparin binding, 
and tissue tropism in different adeno-associated virus serotypes. J Virol 80: 11393–
11397.
 35. Manfredsson, FP, Burger, C, Sullivan, LF, Muzyczka, N, Lewin, AS and Mandel, RJ 
(2007). rAAV-mediated nigral human parkin over-expression partially ameliorates 
motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson’s 
disease. Exp Neurol 207: 289–301.
 36. Aschauer, DF, Kreuz, S and Rumpel, S (2013). Analysis of transduction efficiency, 
tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. 
PLoS One 8: e76310.
 37. Zaiss, AK and Muruve, DA (2005). Immune responses to adeno-associated virus 
vectors. Curr Gene Ther 5: 323–331.
 38. Jacobson, SG, Acland, GM, Aguirre, GD, Aleman, TS, Schwartz, SB, Cideciyan, AV 
et al. (2006). Safety of recombinant adeno-associated virus type 2-RPE65 vector 
delivered by ocular subretinal injection. Mol Ther 13: 1074–1084.
 39. Patel, BA, Dai, X, Burda, JE, Zhao, H, Swain, GM, Galligan, JJ et al. (2010). Inhibitory 
neuromuscular transmission to ileal longitudinal muscle predominates in neonatal 
guinea pigs. Neurogastroenterol Motil 22: 909–18, e236.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 
International License. The images or other third party 
material in this article are included in the article’s Creative 
Commons license, unless indicated otherwise in the credit 
line; if the material is not included under the Creative 
Commons license, users will need to obtain permission 
from the license holder to reproduce the material. To view a 
copy of this license, visit http://creativecommons.org/
licenses/by-nc-nd/4.0/
500 www.moleculartherapy.org vol. 23 no. 3 mar. 2015
